Bulk Drug Substance Sourcing and the Section 503A Lists

Section 503A of the Federal Food, Drug, and Cosmetic Act permits a state-licensed pharmacy to compound a drug product from a bulk drug substance only when that substance meets one of three statutory conditions: it is the subject of an applicable United States Pharmacopeia or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on the FDA 503A Bulks List codified at 21 CFR 216.23. A pharmacy that compounds from a substance satisfying none of the three, or that cannot produce the sourcing record showing which condition applies, has compounded a drug outside section 503A's exemption and faces the same enforcement exposure FDA applies to an unapproved drug manufacturer.

Three Statutory Pathways for a Compounded Bulk Substance

The monograph and approved-drug-component pathways cover most commercially sourced ingredients, since a bulk chemical with a USP or NF monograph, or one already used in an FDA-approved product, needs no separate FDA listing. The third pathway, the 503A Bulks List, exists for substances that fit neither category, most often compounding-specific chemicals such as topical agents and older active ingredients no longer sold as an approved drug. FDA finalized the list's structure at 21 CFR 216.23 in February 2019. The distinction between the 503A and 503B frameworks matters here as well: a substance eligible for a 503A pharmacy is not automatically eligible for a 503B outsourcing facility, which draws from a separate 503B Bulks List and its own drug shortage list allowance.

The Nomination and Evaluation Process

FDA solicited nominations for the 503A Bulks List in 2015 and evaluates each submission against four criteria: the substance's physical and chemical characterization, the safety issues raised by its use in a compounded product, the available evidence of effectiveness, and its historical use in compounding. FDA consults the Pharmacy Compounding Advisory Committee and the United States Pharmacopeial Convention before proposing a determination through notice-and-comment rulemaking. The February 2019 final rule placed six substances on the list, including cantharidin and thymol iodide for topical use only, and declined to list four others, including piracetam and tranilast. A September 2019 proposed rule addressed 31 more nominations, proposing five additions and 26 exclusions, and FDA continues to work through the nomination backlog substance by substance rather than issuing one completed list.

The January 2025 Interim Policy Narrowed the Middle Ground

Before a nominated substance completed rulemaking, FDA had allowed pharmacies to compound with it under a three-category interim system, provided the substance carried no significant safety signal. On January 7, 2025, FDA issued a final interim policy that eliminated that expansion path. Substances already placed in Category 1 retain the interim allowance until FDA completes a final determination, but substances nominated after the cutoff receive no compounding allowance until FDA places them on the final 503A Bulks List. The same sourcing gap has already drawn enforcement scrutiny in adjacent compounding categories, including the tirzepatide compounding enforcement actions that followed the end of the related FDA drug shortage designation.

Sourcing Documentation That Establishes Compliance

An inspector or a PBM auditor reviewing a compounded prescription does not stop at the finished preparation. The file needs to show which of the three section 503A conditions the bulk substance satisfies, a supplier certificate of analysis identifying the substance and lot, and an invoice tying that lot to the pharmacy's purchase. State board compounding inspections increasingly request this pairing alongside the Master Formulation Record, and the same documentation supports the USP 797 and 800 compliance file an inspector reviews for sterile and non-sterile preparations. A pharmacy that substitutes a supplier's assurance for its own sourcing file has no defense once FDA or a state board asks why a given lot was used.

A compounded preparation is only as lawful as the sourcing file behind its bulk drug substance.

Why Early Legal Counsel Is Critical

It is critical that compounding pharmacies retain experienced healthcare defense counsel promptly upon receiving an FDA inspection notice, a state board inquiry, or any request tied to bulk drug substance sourcing. Early legal intervention can protect the pharmacy's rights, ensure the sourcing and Category 1 documentation are gathered and presented correctly, avoid inadvertent admissions about substances used outside section 503A, and preserve the defenses available before an inspection becomes a warning letter or a referral for prosecution. Delaying counsel until after a Form 483 observation narrows the options that were available at the outset.

How Health Law Alliance Can Help

Health Law Alliance represents compounding pharmacies in FDA inspections, state board investigations, and enforcement matters tied to bulk drug substance sourcing under section 503A, as part of the firm's compounding pharmacy defense practice. If your pharmacy needs its 503A Bulks List determinations, Category 1 status, and supplier sourcing file organized before the next inspection, contact us for a free, confidential consultation.